Flomax - Big Patent Expirations of 2010
Drug: Flomax (tamsulosin HCl)
Company: Boehringer Ingelheim
Indication: BPH
Expiration Date: Oct. 27, 2009/Pediatric Exclusivity through April 27
Scoop: Boehringer Ingelheim and Astellas face the loss of exclusivity for their Benign prostatic hyperplasia (BPH) drug Flomax this year. A top Ranbaxy executive has already said that his company will launch a generic version of Flomax in March, allowing the drugmaker to take advantage of its first-to-file status. Teva and Mylan are among the companies looking to sell their generic copies of the BPH drug. The '063 patent that is set to expire has pediatric exclusivity through April 27.
More stories about Flomax
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline

SHARE
WITH: